Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth

Cancer Cell

Volumn 26, Issue 6, 2014, Pages 880-895

  Srivastava, Kshitij ^a   Hu, Junhao ^a   Korn, Claudia ^a   Savant, Soniya ^a,b   Teichert, Martin ^a,b   Kapel, Stephanie S ^a   Jugold, Manfred ^a   Besemfelder, Eva ^a   Thomas, Markus ^c   Pasparakis, Manolis ^d   Augustin, Hellmut G ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2 ANTIBODY; CD11B ANTIGEN; CELL ADHESION MOLECULE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; PROTEIN ANTIBODY; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; LOW DRUG DOSE; LUNG METASTASIS; METRONOMIC DRUG ADMINISTRATION; MICROMETASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPRODUCTIVE TOXICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; BREAST NEOPLASMS; C57BL MOUSE; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; MAXIMUM TOLERATED DOSE; METABOLISM; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919466750     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.11.005     Document Type: Article

References (47)

1. Allegra C.J., Yothers G., O'Connell M.J., Sharif S., Petrelli N.J., Colangelo L.H., Atkins J.N., Seay T.E., Fehrenbacher L., Goldberg R.M., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J.Clin. Oncol. 2011, 29:11-16.
2. Augustin H.G., Koh G.Y., Thurston G., Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
3. Cameron D., Brown J., Dent R., Jackisch C., Mackey J., Pivot X., Steger G.G., Suter T.M., Toi M., Parmar M., et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013, 14:933-942.
4. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
5. Daly C., Eichten A., Castanaro C., Pasnikowski E., Adler A., Lalani A.S., Papadopoulos N., Kyle A.H., Minchinton A.I., Yancopoulos G.D., Thurston G. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013, 73:108-118.
6. de Gramont A., Van Cutsem E., Schmoll H.J., Tabernero J., Clarke S., Moore M.J., Cunningham D., Cartwright T.H., Hecht J.R., Rivera F., et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012, 13:1225-1233.
7. De Palma M., Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin. Cancer Res. 2011, 17:5226-5232.
8. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., Shaked Y., Mancuso P., Goldhirsch A., Rocca A., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J.Clin. Oncol. 2008, 26:4899-4905.
9. Demicheli R., Retsky M.W., Hrushesky W.J., Baum M., Gukas I.D. The effects of surgery on tumor growth: a century of investigations. Ann. Oncol. 2008, 19:1821-1828.
10. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
11. Felcht M., Luck R., Schering A., Seidel P., Srivastava K., Hu J., Bartol A., Kienast Y., Vettel C., Loos E.K., et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J.Clin. Invest. 2012, 122:1991-2005.
12. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
13. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., Groshen S., Swenson S., Markland F., Gandara D., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J.Clin. Oncol. 2008, 26:76-82.
14. Gerald D., Chintharlapalli S., Augustin H.G., Benjamin L.E. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013, 73:1649-1657.
15. Goede V., Coutelle O., Neuneier J., Reinacher-Schick A., Schnell R., Koslowsky T.C., Weihrauch M.R., Cremer B., Kashkar H., Odenthal M., et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br. J. Cancer 2010, 103:1407-1414.
16. Goede V., Coutelle O., Shimabukuro-Vornhagen A., Holtick U., Neuneier J., Koslowsky T.C., Weihrauch M.R., von Bergwelt-Baildon M., Hacker U.T. Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest. 2012, 30:225-230.
17. Hashizume H., Falcón B.L., Kuroda T., Baluk P., Coxon A., Yu D., Bready J.V., Oliner J.D., McDonald D.M. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010, 70:2213-2223.
18. Helfrich I., Scheffrahn I., Bartling S., Weis J., von Felbert V., Middleton M., Kato M., Ergün S., Augustin H.G., Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J.Exp. Med. 2010, 207:491-503.
19. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
20. Holopainen T., Saharinen P., D'Amico G., Lampinen A., Eklund L., Sormunen R., Anisimov A., Zarkada G., Lohela M., Heloterä H., et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J.Natl. Cancer Inst. 2012, 104:461-475.
21. Huang H., Lai J.Y., Do J., Liu D., Li L., Del Rosario J., Doppalapudi V.R., Pirie-Shepherd S., Levin N., Bradshaw C., et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin. Cancer Res. 2011, 17:1001-1011.
22. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
23. Kienast Y., Klein C., Scheuer W., Raemsch R., Lorenzon E., Bernicke D., Herting F., Yu S., The H.H., Martarello L., et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 2013, 19:6730-6740.
24. Kim S., Dobi E., Jary M., Monnien F., Curtit E., Nguyen T., Lakkis Z., Heyd B., Fratte S., Cléau D., et al. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer 2013, 13:611.
25. Kobayashi H., Boelte K.C., Lin P.C. Endothelial cell adhesion molecules and cancer progression. Curr. Med. Chem. 2007, 14:377-386.
26. Koh Y.J., Kim H.Z., Hwang S.I., Lee J.E., Oh N., Jung K., Kim M., Kim K.E., Kim H., Lim N.K., et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010, 18:171-184.
27. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J.Clin. Invest. 2008, 118:3367-3377.
28. Lu X., Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J.Biol. Chem. 2009, 284:29087-29096.
29. Mazzieri R., Pucci F., Moi D., Zonari E., Ranghetti A., Berti A., Politi L.S., Gentner B., Brown J.L., Naldini L., De Palma M. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
30. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U S A 2005, 102:13550-13555.
31. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
32. Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., Johnson M., Lusis A.J., Cohen D.A., Iruela-Arispe M.L., Wu L. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471.
33. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
34. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
35. Qu X., Zhuang G., Yu L., Meng G., Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J.Biol. Chem. 2012, 287:19574-19584.
36. Rigamonti N., Kadioglu E., Keklikoglou I., Wyser Rmili C., Leow C.C., De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Reports 2014, 8:696-706.
37. Sanchez O., Marcos E., Perros F., Fadel E., Tu L., Humbert M., Dartevelle P., Simonneau G., Adnot S., Eddahibi S. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2007, 176:1041-1047.
38. Schauer D., Starlinger P., Reiter C., Jahn N., Zajc P., Buchberger E., Bachleitner-Hofmann T., Bergmann M., Stift A., Gruenberger T., Brostjan C. Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS ONE 2012, 7:e44450.
39. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
40. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., Blanchard D., Bais C., Peale F.V., van Bruggen N., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
41. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U S A 2009, 106:6742-6747.
42. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
43. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., Laudano A., Sebti S., Hamilton A.D., Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J.Biol. Chem. 2001, 276:45443-45455.
44. Wung B.S., Ni C.W., Wang D.L. ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. J.Biomed. Sci. 2005, 12:91-101.
45. Yahata Y., Shirakata Y., Tokumaru S., Yamasaki K., Sayama K., Hanakawa Y., Detmar M., Hashimoto K. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J.Biol. Chem. 2003, 278:40026-40031.
46. Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol. Cell. Biol. 2009, 29:2011-2022.
47. Zagzag D., Hooper A., Friedlander D.R., Chan W., Holash J., Wiegand S.J., Yancopoulos G.D., Grumet M. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol. 1999, 159:391-400.